Outcomes in Chemotherapy-Ineligible Elderly Patients with Newly Diagnosed Acute Myeloid Leukemia Treated with Venetoclax Plus Azacitidine: A Pooled Analysis

被引：1

作者：

Venditti, Adriano ^{[1
]}

Hou, Jing-Zhou ^{[2
]}

Fenaux, Pierre ^{[3
]}

Jonas, Brian A. ^{[4
]}

Vrhovac, Radovan ^{[5
,6
]}

Montesinos, Pau ^{[7
]}

Garcia, Jacqueline S. ^{[8
]}

Rizzieri, David ^{[9
]}

Thirman, Michael J. ^{[10
]}

Kotey, Stanley ^{[11
]}

Potluri, Jalaja ^{[11
]}

Dhalla, Mazaher ^{[11
]}

Pullarkat, Vinod ^{[12
]}

机构：

[1] Univ Roma Tor Vergata, Dept Biomed & Prevent, Rome, Italy

[2] UPMC Hillman Canc Ctr, Lemieux Ctr Blood Canc, Hematol & BMT, Pittsburgh, PA USA

[3] Univ Paris, St Louis Hosp, Dept Hematol, Paris, France

[4] Univ Calif Davis, Div Malignant Hematol Cellular Therapy & Transpla, Dept Internal Med, Sch Med, Sacramento, CA USA

[5] Univ Hosp Ctr Zagreb, Dept Haematol, Zagreb, Croatia

[6] Univ Zagreb, Sch Med, Zagreb, Croatia

[7] Hosp Univ & Politecn La Fe, Valencia, Spain

[8] Harvard Med Sch, Dana Farber Canc Inst, Dept Med Oncol, Boston, MA USA

[9] Novant Hlth Canc Inst, Winston Salem, NC USA

[10] Univ Chicago, Sect Hematol Oncol, Dept Med, Chicago, IL USA

[11] AbbVie Inc, N Chicago, IL USA

[12] City Hope Comprehens Canc Ctr, Dept Hematol & Hematopoiet Cell Transplantat, Duarte, CA USA

来源：

BLOOD | 2023年 / 142卷

关键词：

D O I：

10.1182/blood-2023-182045

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页数：5

共 50 条

[21] Outcomes Are Similar After Allogeneic Hematopoietic Stem Cell Transplant for Newly Diagnosed Acute Myeloid Leukemia Patients who Received Venetoclax plus Azacitidine Versus Intensive Chemotherapy
Winters, Amanda C.
Bosma, Grace
Abbott, Diana
Minhajuddin, Mohd
Jordan, Craig
Pollyea, Daniel A.
Gutman, Jonathan A.
TRANSPLANTATION AND CELLULAR THERAPY, 2022, 28 (10): : 694.e1 - 694.e9
[22] Fungal infection frequency in newly diagnosed acute myeloid leukaemia patients treated with venetoclax plus azacitidine with or without antifungal prophylaxis
Weinbergerova, Barbora
Mayer, Jiri
Kabut, Tomas
Sperr, Wolfgang R.
Stevkova, Jana
Jonasova, Anna
Cernan, Martin
Herndlhofer, Susanne
Oravcova, Iveta
Sramek, Jiri
Novak, Jan
Stepanova, Radka
Szotkowski, Tomas
Drgona, Lubos
Zak, Pavel
Valent, Peter
BRITISH JOURNAL OF HAEMATOLOGY, 2024,
[23] The impact of secondary-type mutations in newly diagnosed acute myeloid leukemia treated with venetoclax and decitabine or azacitidine
Doyel, Michael
Bouligny, Ian Michael
Murray, Graeme
Patel, Tilak
Boron, Josh
Tran, Valerie
Gor, Juhi
Hang, Yiwei
Thuy Ho
Zacholski, Kyle
Venn, Chad Michael
Alnimer, Yanal Mufeed
Wages, Nolan
Grant, Steven
Maher, Keri Renee
JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
[24] A Systematic Review of Venetoclax and Azacitidine: Effectiveness and Safety for Newly Diagnosed and Relapsed Acute Myeloid Leukemia Patients
Ibrahim, Ahmed
Yousaf, Muhammad Abdullah
Anwar, Zain
Anum
Batool, Maha
Rehman, Mohammad
Safdar, Omar A.
Khattak, Zeeshan Ahmed
Faraz, Fatima
Khalid, Huma
BLOOD, 2023, 142
[25] Single-institution experience of venetoclax combined with azacitidine in newly diagnosed acute myeloid leukemia patients
Yu, Hong
Wang, Chaomeng
Lei, Yingying
Li, Lijuan
Wang, Huaquan
Wang, Guojin
Xing, Limin
Guan, Jing
Song, Jia
Wu, Yuhong
Liu, Hong
Qu, Wen
Wang, Xiaoming
Shao, Zonghong
Fu, Rong
INTERNATIONAL IMMUNOPHARMACOLOGY, 2024, 127
[26] Venetoclax for pediatric patients with newly diagnosed acute myeloid leukemia
Gibson, Amber
Dickson, Samantha
McCall, David
Garcia, Miriam
Connors, Jeremy
He, Jiasen
Roth, Michael
Nunez, Cesar
Cuglievan, Branko
PEDIATRIC BLOOD & CANCER, 2024,
[27] Venetoclax combinations induce high response rates in newly diagnosed acute myeloid leukemia patients ineligible for intensive chemotherapy in routine practice
Apel, Arie
Moshe, Yakir
Ofran, Yishai
Gural, Alexander
Wolach, Ofir
Ganzel, Chezi
Canaani, Jonathan
Zektser, Miri
Duek, Adrian
Stemer, Galia
Hellman, Ilana
Basood, May
Frisch, Avraham
Leibovitch, Chiya
Koren-Michowitz, Maya
AMERICAN JOURNAL OF HEMATOLOGY, 2021, 96 (07) : 790 - 795
[28] Molecular characterization of clinical response in patients with newly diagnosed acute myeloid leukemia treated with ivosidenib plus azacitidine compared to placebo plus azacitidine.
De Botton, Stephane
Choe, Sung
Marchione, Dylan M.
Montesinos, Pau
Recher, Christian
Polo, Susana Vives
Zarzycka, Ewa
Wang, Jianxiang
Bertani, Giambattista
Heuser, Michael
Calado, Rodrigo T.
Schuh, Andre C.
Yeh, Su-Peng
Hui, Jianan
Pandya, Shuchi Sumant
Gianolio, Diego A.
Daigle, Scott
Dinardo, Courtney Denton
Dohner, Hartmut
JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
[29] Results of Venetoclax and Azacitidine Combination in Chemotherapy Ineligible Untreated Patients with Acute Myeloid Leukemia with FLT3 Mutations
Konopleva, Marina
Thirman, Michael
Pratz, Keith W.
Letai, Anthony G.
Recher, Christian
Pullarkat, Vinod A.
Kantarjian, Hagop M.
Dail, Monique
Duan, Yinghui
Chyla, Brenda J.
Potluri, Jalaja
Miller, Catherine
Dinardo, Courtney D.
Wei, Andrew H.
BLOOD, 2020, 136
[30] Results of Venetoclax and Azacitidine Combination in Chemotherapy Ineligible Untreated Patients with Acute Myeloid Leukemia with IDH 1/2 Mutations
Pollyea, Daniel A.
Dinardo, Courtney D.
Arellano, Martha L.
Pigneux, Arnaud
Fiedler, Walter
Konopleva, Marina
Rizzieri, David A.
Smith, B. Douglas
Shinagawa, Atsushi
Lemoli, Roberto M.
Dail, Monique
Duan, Yinghui
Chyla, Brenda J.
Potluri, Jalaja
Ridgeway, Jean A.
Kantarjian, Hagop M.
BLOOD, 2020, 136

← 1 2 3 4 5 →